Adagio Medical Achieves Landmark Progress in Q1 2026 with ULTA Platform
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 12 2026
0mins
"The first quarter of 2026 was a landmark period for Adagio during which we made exceptional progress advancing our Ultra-Low Temperature Ablation platform across both clinical development and real-world use," said Todd Usen, Chief Executive Officer of Adagio Medical. "The late-breaking results from the FULCRUM-VT trial represent a defining milestone for our endocardial-only ULTA platform, demonstrating best-in-class safety, 84% freedom from ICD shock at six months, meaningful reductions in antiarrhythmic drug use, and consistent results across both ischemic and non-ischemic cardiomyopathy patients-the broadest patient population studied in any VT ablation trial. The enthusiasm from physicians on the podium was remarkable, with leading electrophysiologists highlighting ULTA as a potentially transformative solution for ventricular tachycardia. As we look ahead, we have multiple additional meaningful milestones expected this year across our platform of technologies and we are more confident than ever in our mission to fundamentally change the treatment of VT with a safe, effective solution for a broad group of patients who suffer from this dangerous arrhythmia."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADGM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADGM
Wall Street analysts forecast ADGM stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.725
Low
4.00
Averages
4.00
High
4.00
Current: 0.725
Low
4.00
Averages
4.00
High
4.00
About ADGM
Adagio Medical Holdings, Inc. is a medical device company. The Company is focused on developing and commercializing products for the treatment of cardiac arrhythmias with catheter-based ultra-low temperature ablation (ULTA) technology, formerly known as ultra-low temperature cryoablation (ULTC) technology. Its initial focus is on the treatment of ventricular tachycardia (VT), which is a rapid, abnormal heart rhythm, or arrhythmia, that originates in the heart’s lower chambers, or ventricles, potentially leading to impaired blood flow and, if sustained, it can be fatal. Its ULTA products are purpose-built to treat patients with VT and are designed to address the unique anatomy of the ventricle and the specific needs of the VT patient. Its catheters and consoles are designed to create titratable, large, durable, deep lesions within the ventricle through a stable, endocardial or inside the heart approach with no required irrigation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Adagio Submits PMA Application for vCLAS System
- Clinical Trial Success: The FULCRUM-VT trial enrolled 209 patients across 20 leading centers, achieving a 97.4% acute clinical success rate, demonstrating the system's effectiveness in treating drug-refractory ventricular tachycardia, which is expected to significantly enhance treatment options for patients.
- Significant Market Potential: The PMA application for the vCLAS system marks the first-ever submission of a purpose-built device in the ventricular ablation market, projected to reach $5.8 billion, positioning Adagio to capture market share and address unmet medical needs with this innovative technology.
- Safety and Efficacy: Trial results indicated that 84.3% of patients experienced freedom from ICD shocks within six months, with only 2.4% major adverse events, highlighting the vCLAS system's superior safety and efficacy, which could redefine treatment standards in cardiology.
- Strategic Implications: Adagio's CEO emphasized that this technology is not just a new approach to VT ablation but a fundamentally better solution aimed at providing uncompromised treatment for all eligible VT patients, signaling the company's leadership position in cardiac care.
See More
Adagio Medical Reports Q1 Financial Results with Reduced Losses
- Financial Highlights: Adagio Medical Holdings reported a Q1 GAAP EPS of -$0.31, which, while still negative, shows improvement compared to -$0.21 in the same period of 2025, indicating gradual financial performance enhancement.
- Reduced Net Loss: For the three months ended March 31, 2026, the company recorded a net loss of $7.0 million, down from $7.7 million in Q1 2025, suggesting progress in cost control and operational efficiency.
- Expense Management: Selling, general, and administrative expenses for Q1 2026 totaled $2.5 million, significantly lower than $3.5 million in Q1 2025, primarily due to reductions in professional services, regulatory reporting, and payroll expenses, reflecting effective spending management.
- Market Implications: Although still in a loss position, the improvement in EPS and effective cost control may boost investor confidence, potentially leading to a positive impact on stock price and indicating the company's future potential.
See More
FULCRUM-VT Trial Demonstrates Effectiveness of Cardiac Ablation Technology
- Clinical Trial Results: The FULCRUM-VT trial demonstrated that 84% of patients experienced no ICD shocks within six months, and 59% had no VT recurrence, indicating the technology's effectiveness in cardiac patients and potentially changing treatment standards.
- Safety Analysis: The trial reported a low major adverse event rate of only 2.4%, showcasing a favorable safety profile, with just 1.9% of patients readmitted for VT-related issues within six months, thereby reducing medical risks for patients.
- Technological Innovation: Adagio's vCLAS ablation system showed equivalent effectiveness in both ischemic and non-ischemic cardiomyopathy patients, marking the first evidence of broad applicability across different pathological backgrounds, which may drive wider clinical adoption.
- Market Potential: With approximately 300,000 sudden cardiac deaths due to ventricular arrhythmias annually in the U.S., the positive results from FULCRUM-VT provide a strong market entry opportunity for Adagio's ULTA technology, expected to attract more investment and improve patient outcomes.
See More
ADAGIO MEDICAL HOLDINGS INC - FULCRUM-VT TRIAL DEMONSTRATES 98% NON-INDUCIBILITY OF TARGETED VT AT PROCEDURE'S CONCLUSION
- Trial Results: A recent trial by AGA Medical Holdings demonstrated a 98% non-inducibility of targeted VT at the end of the procedure.
- Significance: These findings suggest a high efficacy of the treatment method being tested, indicating potential advancements in medical procedures related to VT.
See More
Adagio Medical Receives IDE Approval for vCLAS System Expansion
- Clinical Trial Expansion: Adagio Medical has received Investigational Device Exemption (IDE) approval to expand its FULCRUM-VT trial, evaluating the next-generation vCLAS Ultra-Low Temperature Ablation System for treating sustained monomorphic ventricular tachycardia, marking a significant advancement in cardiac rhythm disorder treatment.
- Technological Innovation: The vCLAS system aims to create effective lesions more efficiently by delivering ultra-cold temperatures around -170 °C, addressing the limitations of current ablation tools that struggle to achieve deep and durable lesions, thereby enhancing treatment outcomes.
- Clinical Study Design: The expanded clinical sub-study will enroll up to 55 patients across multiple centers focusing on scar-mediated SMVT, intending to generate additional safety and effectiveness data to support the pivotal phase of the FULCRUM-VT trial.
- Market Potential: Adagio executives stated that the IDE approval represents an important milestone in advancing technology that could broaden access to VT ablation, with the vCLAS Ultra catheter having the potential to become a scalable endocardial-only solution capable of treating a wide range of VT substrates.
See More
Adagio Receives FDA Approval to Expand Clinical Trial
- Clinical Trial Expansion: Adagio Medical has received FDA approval to expand its FULCRUM-VT trial, evaluating the safety and efficacy of the next-generation vCLAS Ultra-Low Temperature Ablation System for treating Sustained Monomorphic Ventricular Tachycardia (SMVT), marking a significant advancement in cardiac treatment technology.
- Technological Innovation: The new vCLASUltracatheter achieves ablation temperatures of approximately -170°C, significantly enhancing ablation efficiency and reducing ablation time by over 50%, which is expected to improve clinical workflow and patient treatment experience.
- Market Potential: The IDE expansion approval enables Adagio to conduct a prospective, single-arm, multi-center study involving 55 patients, further validating the effectiveness of its technology and aiding the company's penetration and product promotion in the cardiac electrophysiology market.
- Strategic Goals: Adagio aims to translate its ULTA technology into a widely applicable solution, targeting the treatment of a large underserved population suffering from ventricular tachycardia, thereby enhancing the company's leadership position in the cardiac medical device market.
See More
Adagio Submits PMA Application for vCLAS System
- Clinical Trial Success: The FULCRUM-VT trial enrolled 209 patients across 20 leading centers, achieving a 97.4% acute clinical success rate, demonstrating the system's effectiveness in treating drug-refractory ventricular tachycardia, which is expected to significantly enhance treatment options for patients.
- Significant Market Potential: The PMA application for the vCLAS system marks the first-ever submission of a purpose-built device in the ventricular ablation market, projected to reach $5.8 billion, positioning Adagio to capture market share and address unmet medical needs with this innovative technology.
- Safety and Efficacy: Trial results indicated that 84.3% of patients experienced freedom from ICD shocks within six months, with only 2.4% major adverse events, highlighting the vCLAS system's superior safety and efficacy, which could redefine treatment standards in cardiology.
- Strategic Implications: Adagio's CEO emphasized that this technology is not just a new approach to VT ablation but a fundamentally better solution aimed at providing uncompromised treatment for all eligible VT patients, signaling the company's leadership position in cardiac care.
See More
Adagio Medical Reports Q1 Financial Results with Reduced Losses
- Financial Highlights: Adagio Medical Holdings reported a Q1 GAAP EPS of -$0.31, which, while still negative, shows improvement compared to -$0.21 in the same period of 2025, indicating gradual financial performance enhancement.
- Reduced Net Loss: For the three months ended March 31, 2026, the company recorded a net loss of $7.0 million, down from $7.7 million in Q1 2025, suggesting progress in cost control and operational efficiency.
- Expense Management: Selling, general, and administrative expenses for Q1 2026 totaled $2.5 million, significantly lower than $3.5 million in Q1 2025, primarily due to reductions in professional services, regulatory reporting, and payroll expenses, reflecting effective spending management.
- Market Implications: Although still in a loss position, the improvement in EPS and effective cost control may boost investor confidence, potentially leading to a positive impact on stock price and indicating the company's future potential.
See More
FULCRUM-VT Trial Demonstrates Effectiveness of Cardiac Ablation Technology
- Clinical Trial Results: The FULCRUM-VT trial demonstrated that 84% of patients experienced no ICD shocks within six months, and 59% had no VT recurrence, indicating the technology's effectiveness in cardiac patients and potentially changing treatment standards.
- Safety Analysis: The trial reported a low major adverse event rate of only 2.4%, showcasing a favorable safety profile, with just 1.9% of patients readmitted for VT-related issues within six months, thereby reducing medical risks for patients.
- Technological Innovation: Adagio's vCLAS ablation system showed equivalent effectiveness in both ischemic and non-ischemic cardiomyopathy patients, marking the first evidence of broad applicability across different pathological backgrounds, which may drive wider clinical adoption.
- Market Potential: With approximately 300,000 sudden cardiac deaths due to ventricular arrhythmias annually in the U.S., the positive results from FULCRUM-VT provide a strong market entry opportunity for Adagio's ULTA technology, expected to attract more investment and improve patient outcomes.
See More
ADAGIO MEDICAL HOLDINGS INC - FULCRUM-VT TRIAL DEMONSTRATES 98% NON-INDUCIBILITY OF TARGETED VT AT PROCEDURE'S CONCLUSION
- Trial Results: A recent trial by AGA Medical Holdings demonstrated a 98% non-inducibility of targeted VT at the end of the procedure.
- Significance: These findings suggest a high efficacy of the treatment method being tested, indicating potential advancements in medical procedures related to VT.
See More
Adagio Medical Receives IDE Approval for vCLAS System Expansion
- Clinical Trial Expansion: Adagio Medical has received Investigational Device Exemption (IDE) approval to expand its FULCRUM-VT trial, evaluating the next-generation vCLAS Ultra-Low Temperature Ablation System for treating sustained monomorphic ventricular tachycardia, marking a significant advancement in cardiac rhythm disorder treatment.
- Technological Innovation: The vCLAS system aims to create effective lesions more efficiently by delivering ultra-cold temperatures around -170 °C, addressing the limitations of current ablation tools that struggle to achieve deep and durable lesions, thereby enhancing treatment outcomes.
- Clinical Study Design: The expanded clinical sub-study will enroll up to 55 patients across multiple centers focusing on scar-mediated SMVT, intending to generate additional safety and effectiveness data to support the pivotal phase of the FULCRUM-VT trial.
- Market Potential: Adagio executives stated that the IDE approval represents an important milestone in advancing technology that could broaden access to VT ablation, with the vCLAS Ultra catheter having the potential to become a scalable endocardial-only solution capable of treating a wide range of VT substrates.
See More
Adagio Receives FDA Approval to Expand Clinical Trial
- Clinical Trial Expansion: Adagio Medical has received FDA approval to expand its FULCRUM-VT trial, evaluating the safety and efficacy of the next-generation vCLAS Ultra-Low Temperature Ablation System for treating Sustained Monomorphic Ventricular Tachycardia (SMVT), marking a significant advancement in cardiac treatment technology.
- Technological Innovation: The new vCLASUltracatheter achieves ablation temperatures of approximately -170°C, significantly enhancing ablation efficiency and reducing ablation time by over 50%, which is expected to improve clinical workflow and patient treatment experience.
- Market Potential: The IDE expansion approval enables Adagio to conduct a prospective, single-arm, multi-center study involving 55 patients, further validating the effectiveness of its technology and aiding the company's penetration and product promotion in the cardiac electrophysiology market.
- Strategic Goals: Adagio aims to translate its ULTA technology into a widely applicable solution, targeting the treatment of a large underserved population suffering from ventricular tachycardia, thereby enhancing the company's leadership position in the cardiac medical device market.
See More
